The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Decibel Therapeutics, which is developing preclinical gene therapies for hearing loss and balance disorders, raised $127 million by offering 7.1 million shares at $18, the high end of the range of $16 to $18. The company had originally filed to sell 5.9 million...read more
Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $100 million by offering 5.9 million shares at a price range of $16 to $18....read more
Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering. Decibel Therapeutics aims to restore and improve hearing and balance...read more
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Decibel Therapeutics prices upsized IPO at $18, the high end of the range
Decibel Therapeutics, which is developing preclinical gene therapies for hearing loss and balance disorders, raised $127 million by offering 7.1 million shares at $18, the high end of the range of $16 to $18. The company had originally filed to sell 5.9 million...read more
Hearing disorder biotech Decibel Therapeutics sets terms for $100 million IPO
Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $100 million by offering 5.9 million shares at a price range of $16 to $18....read more
Hearing disorder biotech Decibel Therapeutics files for a $75 million IPO
Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering. Decibel Therapeutics aims to restore and improve hearing and balance...read more